Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) - Net Assets
Based on the latest financial reports, Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has net assets worth CN¥5.73 Billion CNY (≈ $838.11 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.10 Billion ≈ $892.79 Million USD) and total liabilities (CN¥373.70 Million ≈ $54.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Wuhan Easy Diagnosis Biomedicine Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.73 Billion |
| % of Total Assets | 93.87% |
| Annual Growth Rate | 162.43% |
| 5-Year Change | 439.85% |
| 10-Year Change | 5115.99% |
| Growth Volatility | 1714.12 |
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Net Assets Trend (2011–2024)
This chart illustrates how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. Also explore Wuhan Easy Diagnosis Biomedicine Co Ltd (002932) total assets for the complete picture of this company's asset base.
Annual Net Assets for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2024)
The table below shows the annual net assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2024. For live valuation and market cap data, see how much is Wuhan Easy Diagnosis Biomedicine Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.02 Billion ≈ $880.72 Million |
-4.35% |
| 2023-12-31 | CN¥6.29 Billion ≈ $920.73 Million |
-7.08% |
| 2022-12-31 | CN¥6.77 Billion ≈ $990.93 Million |
+137.60% |
| 2021-12-31 | CN¥2.85 Billion ≈ $417.06 Million |
+155.64% |
| 2020-12-31 | CN¥1.11 Billion ≈ $163.14 Million |
+81.10% |
| 2019-12-31 | CN¥615.62 Million ≈ $90.08 Million |
+3.89% |
| 2018-12-31 | CN¥592.59 Million ≈ $86.72 Million |
+143.93% |
| 2017-12-31 | CN¥242.93 Million ≈ $35.55 Million |
+38.76% |
| 2016-12-31 | CN¥175.08 Million ≈ $25.62 Million |
+51.73% |
| 2015-12-31 | CN¥115.39 Million ≈ $16.89 Million |
+132.69% |
| 2014-12-31 | CN¥49.59 Million ≈ $7.26 Million |
+264.74% |
| 2013-12-31 | CN¥13.60 Million ≈ $1.99 Million |
+855.19% |
| 2012-12-31 | CN¥1.42 Million ≈ $208.28K |
+6535.83% |
| 2011-12-31 | CN¥21.45K ≈ $3.14K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 438412623830.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.38 Billion | 75.23% |
| Common Stock | CN¥232.52 Million | 3.99% |
| Other Components | CN¥1.21 Billion | 20.78% |
| Total Equity | CN¥5.83 Billion | 100.00% |
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Competitors by Market Cap
The table below lists competitors of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret AS
IS:BRISA
|
$577.46 Million |
|
YLZ Information Tech Co
SHE:300096
|
$577.63 Million |
|
Capex S.A
BA:CAPX
|
$577.67 Million |
|
Chengdu Screen Micro-Electronics Co. Ltd. A
SHG:688053
|
$578.01 Million |
|
Polyrocks Chemical Co Ltd
SHG:688669
|
$577.03 Million |
|
Zhejiang Jiaxin Silk Corp Ltd
SHE:002404
|
$576.95 Million |
|
Taiwan Sakura Corp
TW:9911
|
$576.88 Million |
|
Sanlux Co Ltd
SHE:002224
|
$576.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,025,889,662 to 5,826,392,063, a change of -199,497,599 (-3.3%).
- Net income of 74,519,615 contributed positively to equity growth.
- Dividend payments of 47,385,071 reduced retained earnings.
- Share repurchases of 238,163,916 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥74.52 Million | +1.28% |
| Dividends Paid | CN¥47.39 Million | -0.81% |
| Share Repurchases | CN¥238.16 Million | -4.09% |
| Other Changes | CN¥11.53 Million | +0.2% |
| Total Change | CN¥- | -3.31% |
Book Value vs Market Value Analysis
This analysis compares Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.65x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥3557.05 | CN¥16.97 | x |
| 2012-12-31 | CN¥0.06 | CN¥16.97 | x |
| 2013-12-31 | CN¥0.23 | CN¥16.97 | x |
| 2014-12-31 | CN¥0.35 | CN¥16.97 | x |
| 2015-12-31 | CN¥0.78 | CN¥16.97 | x |
| 2016-12-31 | CN¥1.13 | CN¥16.97 | x |
| 2017-12-31 | CN¥1.55 | CN¥16.97 | x |
| 2018-12-31 | CN¥3.33 | CN¥16.97 | x |
| 2019-12-31 | CN¥2.93 | CN¥16.97 | x |
| 2020-12-31 | CN¥5.28 | CN¥16.97 | x |
| 2021-12-31 | CN¥13.18 | CN¥16.97 | x |
| 2022-12-31 | CN¥28.27 | CN¥16.97 | x |
| 2023-12-31 | CN¥26.46 | CN¥16.97 | x |
| 2024-12-31 | CN¥26.13 | CN¥16.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wuhan Easy Diagnosis Biomedicine Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 21.29%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.13x
- Recent ROE (1.28%) is below the historical average (117.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 1180.66% | 20.79% | 0.62x | 91.26x | CN¥251.09K |
| 2012 | 98.49% | 19.76% | 1.52x | 3.27x | CN¥1.26 Million |
| 2013 | 53.86% | 28.22% | 1.09x | 1.75x | CN¥5.96 Million |
| 2014 | 43.44% | 37.26% | 0.95x | 1.23x | CN¥16.58 Million |
| 2015 | 30.85% | 37.34% | 0.71x | 1.16x | CN¥24.06 Million |
| 2016 | 34.09% | 42.34% | 0.72x | 1.13x | CN¥42.18 Million |
| 2017 | 27.22% | 39.66% | 0.64x | 1.07x | CN¥41.44 Million |
| 2018 | 10.44% | 34.82% | 0.29x | 1.05x | CN¥2.60 Million |
| 2019 | 6.81% | 22.92% | 0.28x | 1.05x | CN¥-19.45 Million |
| 2020 | 42.56% | 48.89% | 0.67x | 1.29x | CN¥358.75 Million |
| 2021 | 50.67% | 49.94% | 0.83x | 1.23x | CN¥1.13 Billion |
| 2022 | 64.75% | 39.97% | 1.15x | 1.41x | CN¥3.56 Billion |
| 2023 | 1.24% | 10.00% | 0.10x | 1.23x | CN¥-527.66 Million |
| 2024 | 1.28% | 21.29% | 0.05x | 1.13x | CN¥-508.12 Million |
Industry Comparison
This section compares Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,140,494,188
- Average return on equity (ROE) among peers: 16.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | CN¥5.73 Billion | 1180.66% | 0.07x | $577.41 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $1.09 Billion | 22.08% | 0.18x | $449.34 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $6.16 Billion | 12.22% | 0.29x | $4.30 Billion |
| Double Medical Technology Inc (002901) | $1.46 Billion | 25.48% | 0.14x | $2.63 Billion |
| Lepu Medical Tech Beijing (300003) | $3.29 Billion | 12.85% | 0.16x | $3.87 Billion |
| INKON Life Technology Co Ltd (300143) | $810.78 Million | 0.80% | 0.23x | $1.23 Billion |
| Edan Instruments Inc (300206) | $152.19 Million | 30.16% | 0.31x | $1.26 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.03 Billion | 33.51% | 0.56x | $685.28 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.80 Billion | 0.85% | 0.07x | $534.16 Million |
| Sinocare Inc (300298) | $3.47 Billion | 8.19% | 0.71x | $1.36 Billion |
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more